<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02239835</url>
  </required_header>
  <id_info>
    <org_study_id>1182.4</org_study_id>
    <nct_id>NCT02239835</nct_id>
  </id_info>
  <brief_title>Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients</brief_title>
  <official_title>Tipranavir: An Open-label, Randomized Study Comparing Combination Therapy (Tipranavir and Ritonavir vs. Saquinavir and Ritonavir) Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Objectives of the study were to evaluate the efficacy and safety of two different doses of&#xD;
      tipranavir (TPV) in combination with ritonavir (TPV/r) compared with a standard dual PI&#xD;
      combination of saquinavir (SQV) and ritonavir (RTV) and to evaluate the dose response of two&#xD;
      different doses of TPV in combination with RTV for efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">November 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in plasma HIV-1 RNA concentrations</measure>
    <time_frame>Week 16, 24 and 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>using the Roche Amplicor HIV Monitor™ Method [limit of detection (LD) 400 copies/mL] and the Roche Amplicor UltraSensitive Method™ (LD 50 copies/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment-emergent and drug-related adverse events (AEs)</measure>
    <time_frame>up to 96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with serious adverse events (SAEs)</measure>
    <time_frame>up to 96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with grade 3 and 4 laboratory abnormalities</measure>
    <time_frame>up to 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation (CD) 4+ cell count</measure>
    <time_frame>Week 16, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virologic failure</measure>
    <time_frame>after week 16</time_frame>
    <description>defined as plasma HIV-1 RNA values &gt;400 copies/mL at two consecutive time points 2 to 4 weeks apart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new or recurring AIDS-defining illnesses</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of HIV-1 related illness</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to new or recurring AIDS-defining illnesses</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HIV-1 related illness</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood glucose</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cholesterol</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in high density lipoprotein (HDL)</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in triglycerides</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virologic response</measure>
    <time_frame>up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma tipranavir concentrations</measure>
    <time_frame>up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequence-based HIV-1 analysis (genotyping) and drug susceptibility assays (phenotyping)</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>TPV low dose + RTV low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV high dose + RTV low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SQV + RTV high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir (TPV) low dose</intervention_name>
    <arm_group_label>TPV low dose + RTV low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir (TPV) high dose</intervention_name>
    <arm_group_label>TPV high dose + RTV low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir low dose</intervention_name>
    <arm_group_label>TPV high dose + RTV low dose</arm_group_label>
    <arm_group_label>TPV low dose + RTV low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir high dose</intervention_name>
    <arm_group_label>SQV + RTV high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir</intervention_name>
    <arm_group_label>SQV + RTV high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical failure while on the current PI-containing regimen of indinavir, nelfinavir,&#xD;
             or amprenavir&#xD;
&#xD;
          -  In the investigator's opinion, adherence to the present PI-containing regimen&#xD;
&#xD;
          -  Exposure of &gt;=6 months to the current PI therapy&#xD;
&#xD;
          -  Stable PI-containing regimen, i.e., receiving the current two reverse transcriptase&#xD;
             inhibitors (RTIs) for at least 2 months prior to study entry&#xD;
&#xD;
          -  HIV-1 RNA &gt;=1000 copies/mL (assayed using the Amplicor polymerase chain reaction (PCR)&#xD;
             method at the initial screening visit)&#xD;
&#xD;
          -  No limit in CD4+ cell count at the initial screening&#xD;
&#xD;
          -  At least two new nucleoside reverse transcriptase inhibitor (NRTI) options available&#xD;
&#xD;
          -  Age &gt;=18 years&#xD;
&#xD;
          -  Acceptable screening laboratory test values that indicated adequate baseline organ&#xD;
             function at the time of screening. Acceptable laboratory test values consisted of the&#xD;
             following: severity &lt;=Grade 1 (ACTG Grading Scale). Stable Grade 2 abnormalities were&#xD;
             permitted if the values had been demonstrated and documented for at least &gt;=2 months.&#xD;
             All laboratory values &gt;Grade 2 were subject to approval by the P&amp;U Clinical Program&#xD;
             Leader or designated personnel and subsequently by the BI designated personnel&#xD;
&#xD;
          -  Acceptable medical history, physical examination, ECG, and chest radiograph prior to&#xD;
             entry into the treatment phase of the study&#xD;
&#xD;
          -  Use of a barrier contraceptive method of birth control for at least 30 days prior to&#xD;
             study drug administration, during the study, and 30 days after study completion&#xD;
&#xD;
          -  Ability to swallow numerous tablets and capsules without difficulty&#xD;
&#xD;
          -  Ability to understand and provide informed consent. Minors had to have approval of a&#xD;
             parent or legal guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with more than one PI-containing regimen&#xD;
&#xD;
          -  Clinically significant active or acute (onset within the month previous to study&#xD;
             entry) medical problems, including the following: opportunistic infections, e.g.,&#xD;
             active cryptococcosis, Pneumocystis carinii pneumonia, herpes zoster, histoplasmosis,&#xD;
             or cytomegalovirus; nonopportunistic diseases, including but not limited to the&#xD;
             following: progressive multifocal leukoencephalopathy, lymphoma, or malignancy&#xD;
             requiring systemic therapy&#xD;
&#xD;
          -  Prior exposure (&gt;7 days) to tipranavir, saquinavir, or ritonavir&#xD;
&#xD;
          -  History of clinically significant nervous system or muscle diseases, seizure disorder,&#xD;
             or psychiatric disorder that might impair adherence to the protocol&#xD;
&#xD;
          -  Taking of any known P450 3A enzyme-inducing drugs within 30 days of study entry and&#xD;
             including the following: rifabutin, rifampin, carbamazepine, dexamethasone,&#xD;
             phenobarbital, phenytoin, sulfadimidine, sulfinpyrazone, or troleandomycin&#xD;
&#xD;
          -  Hypersensitivity to tipranavir, saquinavir, or ritonavir&#xD;
&#xD;
          -  Use of interferons, interleukins, HIV vaccines, or any active immunizations within 30&#xD;
             days of study entry&#xD;
&#xD;
          -  Taking of any investigational medication with the exception of adefovir dipivoxil&#xD;
             (Preveon™) within 30 days of study entry&#xD;
&#xD;
          -  Pregnancy or lactation (serum β-human chorionic gonadotrophin test had to have been&#xD;
             negative within 14 days of study entry)&#xD;
&#xD;
          -  Evidence of substance abuse, which in the investigator's opinion could affect&#xD;
             adherence to the protocol&#xD;
&#xD;
          -  In the investigator's judgment, inability to comply with the protocol requirements for&#xD;
             reasons other than those specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2014</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

